Annual CFO
-$17.49 M
+$10.84 M+38.26%
31 December 2023
Summary:
AcelRx Pharmaceuticals annual cash flow from operations is currently -$17.49 million, with the most recent change of +$10.84 million (+38.26%) on 31 December 2023. During the last 3 years, it has risen by +$12.51 million (+41.70%).ACRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$3.95 M
-$989.00 K-33.41%
31 December 2023
Summary:
AcelRx Pharmaceuticals quarterly cash flow from operations is currently -$3.95 million, with the most recent change of -$989.00 thousand (-33.41%) on 31 December 2023.ACRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$17.49 M
+$1.46 M+7.72%
31 December 2023
Summary:
AcelRx Pharmaceuticals TTM cash flow from operations is currently -$17.49 million, with the most recent change of +$1.46 million (+7.72%) on 31 December 2023.ACRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +41.7% | +50.7% | +41.7% |
| 5 y5 years | +65.8% | +72.1% | +65.8% |
ACRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | +3491.8% | -115.5% | >+9999.0% |
AcelRx Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | -$17.49 M(-38.3%) | -$3.95 M(+33.4%) | -$17.49 M(-7.7%) |
| Sept 2023 | - | -$2.96 M(-44.5%) | -$18.96 M(-10.7%) |
| June 2023 | - | -$5.33 M(+1.6%) | -$21.23 M(-13.8%) |
| Mar 2023 | - | -$5.25 M(-3.0%) | -$24.65 M(-13.0%) |
| Dec 2022 | -$28.33 M(-5.6%) | -$5.41 M(+3.3%) | -$28.33 M(-8.4%) |
| Sept 2022 | - | -$5.24 M(-40.1%) | -$30.92 M(+4.4%) |
| June 2022 | - | -$8.75 M(-2.1%) | -$29.63 M(+1.4%) |
| Mar 2022 | - | -$8.93 M(+11.6%) | -$29.23 M(-2.6%) |
| Dec 2021 | -$30.00 M(-22.1%) | -$8.00 M(+103.0%) | -$30.00 M(+5.9%) |
| Sept 2021 | - | -$3.94 M(-52.8%) | -$28.32 M(-12.9%) |
| June 2021 | - | -$8.35 M(-14.0%) | -$32.51 M(-4.0%) |
| Mar 2021 | - | -$9.71 M(+53.4%) | -$33.85 M(-12.1%) |
| Dec 2020 | -$38.51 M(-24.8%) | -$6.33 M(-22.1%) | -$38.51 M(-16.9%) |
| Sept 2020 | - | -$8.12 M(-16.2%) | -$46.33 M(-6.7%) |
| June 2020 | - | -$9.69 M(-32.5%) | -$49.67 M(-5.0%) |
| Mar 2020 | - | -$14.36 M(+1.5%) | -$52.30 M(+2.2%) |
| Dec 2019 | -$51.18 M(+76.0%) | -$14.15 M(+23.5%) | -$51.18 M(+11.2%) |
| Sept 2019 | - | -$11.47 M(-6.9%) | -$46.02 M(+12.6%) |
| June 2019 | - | -$12.32 M(-7.0%) | -$40.85 M(+16.9%) |
| Mar 2019 | - | -$13.24 M(+47.3%) | -$34.94 M(+20.2%) |
| Dec 2018 | -$29.07 M(-2.3%) | -$8.99 M(+42.7%) | -$29.07 M(+8.6%) |
| Sept 2018 | - | -$6.30 M(-1.7%) | -$26.76 M(-1.8%) |
| June 2018 | - | -$6.41 M(-13.1%) | -$27.24 M(-8.0%) |
| Mar 2018 | - | -$7.37 M(+10.5%) | -$29.60 M(-0.5%) |
| Dec 2017 | -$29.77 M(+1.3%) | -$6.68 M(-1.6%) | -$29.77 M(-10.9%) |
| Sept 2017 | - | -$6.78 M(-22.6%) | -$33.40 M(+7.0%) |
| June 2017 | - | -$8.77 M(+16.4%) | -$31.23 M(+1.7%) |
| Mar 2017 | - | -$7.54 M(-27.0%) | -$30.70 M(+4.4%) |
| Dec 2016 | -$29.39 M | -$10.31 M(+123.6%) | -$29.39 M(+143.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2016 | - | -$4.61 M(-44.0%) | -$12.09 M(-6.9%) |
| June 2016 | - | -$8.24 M(+32.3%) | -$12.98 M(-15.9%) |
| Mar 2016 | - | -$6.23 M(-189.0%) | -$15.43 M(-22.7%) |
| Dec 2015 | -$19.95 M(-42.1%) | $7.00 M(-227.0%) | -$19.95 M(-44.4%) |
| Sept 2015 | - | -$5.51 M(-48.5%) | -$35.87 M(-0.2%) |
| June 2015 | - | -$10.69 M(-0.6%) | -$35.95 M(+2.5%) |
| Mar 2015 | - | -$10.75 M(+20.5%) | -$35.07 M(+1.8%) |
| Dec 2014 | -$34.46 M(+6975.2%) | -$8.92 M(+59.5%) | -$34.46 M(>+9900.0%) |
| Sept 2014 | - | -$5.59 M(-43.0%) | -$87.00 K(-93.5%) |
| June 2014 | - | -$9.81 M(-3.2%) | -$1.33 M(+40.9%) |
| Mar 2014 | - | -$10.13 M(-139.8%) | -$947.00 K(+94.5%) |
| Dec 2013 | -$487.00 K(-98.0%) | $25.45 M(-472.1%) | -$487.00 K(-98.5%) |
| Sept 2013 | - | -$6.84 M(-27.4%) | -$31.73 M(+0.5%) |
| June 2013 | - | -$9.42 M(-2.6%) | -$31.58 M(+19.2%) |
| Mar 2013 | - | -$9.67 M(+66.8%) | -$26.49 M(+7.8%) |
| Dec 2012 | -$24.58 M(+60.8%) | -$5.80 M(-13.2%) | -$24.58 M(-0.8%) |
| Sept 2012 | - | -$6.68 M(+54.0%) | -$24.77 M(+10.8%) |
| June 2012 | - | -$4.34 M(-44.1%) | -$22.36 M(+3.2%) |
| Mar 2012 | - | -$7.76 M(+29.5%) | -$21.67 M(+41.8%) |
| Dec 2011 | -$15.29 M(+25.0%) | -$5.99 M(+40.3%) | -$15.29 M(+22.5%) |
| Sept 2011 | - | -$4.27 M(+17.0%) | -$12.48 M(+17.6%) |
| June 2011 | - | -$3.65 M(+165.5%) | -$10.61 M(+5.6%) |
| Mar 2011 | - | -$1.38 M(-56.8%) | -$10.05 M(-17.8%) |
| Dec 2010 | -$12.22 M(-37.0%) | -$3.18 M(+32.6%) | -$12.22 M(+35.2%) |
| Sept 2010 | - | -$2.40 M(-22.3%) | -$9.04 M(+36.1%) |
| June 2010 | - | -$3.09 M(-13.0%) | -$6.64 M(+87.0%) |
| Mar 2010 | - | -$3.55 M | -$3.55 M |
| Dec 2009 | -$19.42 M(+2.7%) | - | - |
| Dec 2008 | -$18.90 M | - | - |
FAQ
- What is AcelRx Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for AcelRx Pharmaceuticals?
- What is AcelRx Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for AcelRx Pharmaceuticals?
What is AcelRx Pharmaceuticals annual cash flow from operations?
The current annual CFO of ACRX is -$17.49 M
What is the all time high annual CFO for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high annual cash flow from operations is -$487.00 K
What is AcelRx Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ACRX is -$3.95 M
What is the all time high quarterly CFO for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high quarterly cash flow from operations is $25.45 M
What is AcelRx Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ACRX is -$17.49 M
What is the all time high TTM CFO for AcelRx Pharmaceuticals?
AcelRx Pharmaceuticals all-time high TTM cash flow from operations is -$87.00 K